FibroBiologics CFO Andersen Resigns

Dow Jones

Oct 30, 2024

By Adam L. Cataldo

FibroBiologics Chief Financial Officer Mark Andersen has resigned to pursue other opportunities, the company said.

Andersen informed the biotechnology company of his decision on Oct. 25, according to a filing Tuesday with the Securities and Exchange Commission. His resignation will become effective when a new or interim CFO is appointed, or on his date of resignation, Nov. 15, whichever comes first.

Andersen will remain employed as CFO, but will no longer have the powers, duties and responsibilities that come with the position. His main responsibility will be to transition his duties and knowledge to his successor, the company said.

Write to Adam Cataldo at adam.cataldo@wsj.com

(END) Dow Jones Newswires

October 29, 2024 19:38 ET (23:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2479674072"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479674072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479674072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 07:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479674072","market":"other","top_or_hot":-1,"title":"FibroBiologics CFO Andersen Resigns","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adam L. Cataldo \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> Chief Financial Officer Mark Andersen has resigned to pursue other opportunities, the company said. \n</p>\n<p>\n  Andersen informed the biotechnology company of his decision on Oct. 25, according to a filing Tuesday with the Securities and Exchange Commission. His resignation will become effective when a new or interim CFO is appointed, or on his date of resignation, Nov. 15, whichever comes first. \n</p>\n<p>\n  Andersen will remain employed as CFO, but will no longer have the powers, duties and responsibilities that come with the position. His main responsibility will be to transition his duties and knowledge to his successor, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adam Cataldo at adam.cataldo@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2024 19:38 ET (23:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroBiologics CFO Andersen Resigns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroBiologics CFO Andersen Resigns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-30 07:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adam L. Cataldo \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> Chief Financial Officer Mark Andersen has resigned to pursue other opportunities, the company said. \n</p>\n<p>\n  Andersen informed the biotechnology company of his decision on Oct. 25, according to a filing Tuesday with the Securities and Exchange Commission. His resignation will become effective when a new or interim CFO is appointed, or on his date of resignation, Nov. 15, whichever comes first. \n</p>\n<p>\n  Andersen will remain employed as CFO, but will no longer have the powers, duties and responsibilities that come with the position. His main responsibility will be to transition his duties and knowledge to his successor, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adam Cataldo at adam.cataldo@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2024 19:38 ET (23:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FBLG","symbol_name":"FibroBiologics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479674072","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479674072","pubTimestamp":1730245080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"FibroBiologics Chief Financial Officer Mark Andersen has resigned to pursue other opportunities, the company said.Andersen informed the biotechnology company of his decision on Oct. 25, according to a filing Tuesday with the Securities and Exchange Commission. His resignation will become effective when a new or interim CFO is appointed, or on his date of resignation, Nov. 15, whichever comes first.Andersen will remain employed as CFO, but will no longer have the powers, duties and responsibilities that come with the position. His main responsibility will be to transition his duties and knowledge to his successor, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FBLG":"FibroBiologics","BK4139":"生物科技"},"translate_title":"FibroBiologics首席财务官安德森辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBLG":1},"content_text":"By Adam L. Cataldo \n\n\n \n\n\nFibroBiologics Chief Financial Officer Mark Andersen has resigned to pursue other opportunities, the company said. \n\n\n  Andersen informed the biotechnology company of his decision on Oct. 25, according to a filing Tuesday with the Securities and Exchange Commission. His resignation will become effective when a new or interim CFO is appointed, or on his date of resignation, Nov. 15, whichever comes first. \n\n\n  Andersen will remain employed as CFO, but will no longer have the powers, duties and responsibilities that come with the position. His main responsibility will be to transition his duties and knowledge to his successor, the company said. \n\n\n \n\n\n  Write to Adam Cataldo at adam.cataldo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2024 19:38 ET (23:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}